ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”
October 2023, Healthcare Executive Magzine released the lists of “Top 100 Chinese Pharmaceutical Innovative Enterprises in 2023” and “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”. Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. (ProteLight Pharma) was selected as “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises”, which is the 2nd consecutive year to be selected into the list since 2022. ProteLight Pharma has the ability to prosperous in the current trough of the pharmaceutical industry, and the ability to continuously push forward the new drug clinical trials and a multiple of product pipelines. It represents that ProteLight Pharma not only has a sound value and methodology, but also shows that the new force of the pharmaceutical industry is thriving.
Below is the “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023” list:
“Top 100 Innovative Seed Enterprises” continues the basic research framework of the “Top 100 Innovative Enterprises”, with innovation foundations, innovation processes, and innovoation achievements as the main evaluation system, and based on Derwent Innovation patent data of the Clarivate Analytics, Cortellis™ competitive intelligence and clinical trial data.The lists were selected from more than 5000 Chinese pharmaceutical companies through the number of authorized patents, total number of patent citations, number of clinical trials under research, and number of approved and marketed new drugs.